<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03895684</url>
  </required_header>
  <id_info>
    <org_study_id>SALA-003-AC19</org_study_id>
    <nct_id>NCT03895684</nct_id>
  </id_info>
  <brief_title>Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors</brief_title>
  <official_title>Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Salarius Pharmaceuticals, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Salarius Pharmaceuticals, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1, open-label, non-randomized dose finding study of SP-2577 in patients with advanced&#xD;
      solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1, open-label, non-randomized dose finding study of SP-2577 given as oral tablets in&#xD;
      patients with advanced solid tumors in 28-day cycles. The study design is based on a Simon's&#xD;
      4B design without intrapatient dose escalation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 25, 2019</start_date>
  <completion_date type="Actual">April 13, 2021</completion_date>
  <primary_completion_date type="Actual">April 13, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This single arm study will utilize an accelerated dose escalation, followed by a conventional 3+3 dose escalation phase to achieve maximum tolerated dose (MTD).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of SP-2577</measure>
    <time_frame>From screening through at least 30 days after end of treatment, up to approximately 24 months</time_frame>
    <description>Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the maximum tolerated dose of SP-2577</measure>
    <time_frame>DLTs within the first cycle of therapy (up to 28 days)</time_frame>
    <description>Defined as the dose level immediately below the dose level at which ≥ 2 patients from a cohort of 3 to 6 patients experience a dose-limiting toxicity (DLT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of pharmacokinetics of SP-2577 (area under the concentration time profile)</measure>
    <time_frame>At protocol defined time points on cycle 1 (each cycle is 28 days), day 1 and 2 and cycle 2, day 1 and 2.</time_frame>
    <description>SP-2577 under fasted and fed conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of pharmacokinetics of SP-2577 (time to maximum plasma concentration)</measure>
    <time_frame>At protocol defined time points on cycle 1 (each cycle is 28 days), day 1 and 2 and cycle 2, day 1 and 2.</time_frame>
    <description>SP-2577 under fasted and fed conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of pharmacokinetics of SP-2577 (maximum plasma concentration)</measure>
    <time_frame>At protocol defined time points on cycle 1 (each cycle is 28 days), day 1 and 2 and cycle 2, day 1 and 2.</time_frame>
    <description>SP-2577 under fasted and fed conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of pharmacokinetics of SP-2577 (half-life)</measure>
    <time_frame>At protocol defined time points on cycle 1 (each cycle is 28 days), day 1 and 2 and cycle 2, day 1 and 2.</time_frame>
    <description>SP-2577 under fasted and fed conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of pharmacokinetics of SP-2577 (clearance rate)</measure>
    <time_frame>At protocol defined time points on cycle 1 (each cycle is 28 days), day 1 and 2 and cycle 2, day 1 and 2.</time_frame>
    <description>SP-2577 under fasted and fed conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of pharmacokinetics of SP-2577 (volume of distribution)</measure>
    <time_frame>At protocol defined time points on cycle 1 (each cycle is 28 days), day 1 and 2 and cycle 2, day 1 and 2.</time_frame>
    <description>SP-2577 under fasted and fed conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy parameter: overall response rate of SP-2577</measure>
    <time_frame>From start of treatment through at least 30 days after end of treatment, up to approximately 24 months</time_frame>
    <description>Assessed by radiographic imaging with response and progression evaluated by RECIST 1.1 guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy parameter: duration of response of SP-2577</measure>
    <time_frame>From start of treatment through at least 30 days after end of treatment, up to approximately 24 months</time_frame>
    <description>Assessed by radiographic imaging with response and progression evaluated by RECIST 1.1 guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy parameter: progression-free survival of SP-2577</measure>
    <time_frame>From start of treatment through at least 30 days after end of treatment, up to approximately 24 months</time_frame>
    <description>Assessed by radiographic imaging with response and progression evaluated by RECIST 1.1 guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum hemoglobin F concentrations</measure>
    <time_frame>At protocol defined time points from start of treatment through end of treatment, up to approximately 24 months</time_frame>
    <description>Determine changes serum hemoglobin F concentrations correlated with SP-2577 treatment and clinical and radiographic markers of disease burden (either response or resistance/progression).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the molecular signatures of the tumor</measure>
    <time_frame>At protocol defined time points from start of treatment through end of treatment, up to approximately 24 months</time_frame>
    <description>Assessed in dose expansion only by RNA-seq testing of tumor biopsy samples to determine changes in gene expression patterns by SP-2577 treatment to elucidate biological changes induced in the tumor by LSD1 inhibition.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Sp-2577</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice-daily administration of oral SP-2577</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SP-2577 Seclidemstat</intervention_name>
    <description>Dose escalation and dose expansion of SP-2577.</description>
    <arm_group_label>Sp-2577</arm_group_label>
    <other_name>LSD1 Inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 12 years and weight ≥ 40 kg.&#xD;
&#xD;
          -  Diagnosis of advanced or recurrent, histologically or cytologically confirmed, solid&#xD;
             malignancy that is either metastatic or unresectable. At time of enrollment, subjects&#xD;
             must have progressed on, be intolerant of, refuse, or ineligible for, all available&#xD;
             standard of care therapies.&#xD;
&#xD;
          -  Subjects must demonstrate measurable disease per Response Evaluation Criteria in Solid&#xD;
             Tumors (RECIST) v1.1, with the exception of castration-resistant prostate cancer&#xD;
             (CRPC) who should have progression based on the PCWG 3.0 criteria&#xD;
&#xD;
          -  Karnofsky ≥70% for over ≥16 years old and Lansky ≥70% for under 16 years old,&#xD;
             equivalent to Eastern Cooperative Oncology Group (ECOG) performance status grade 0 or&#xD;
             1&#xD;
&#xD;
          -  Willingness to provide tumor biopsies of assessible lesions on and off treatment (Dose&#xD;
             expansion cohort only). Optional for patients &lt;18 years of age.&#xD;
&#xD;
          -  Able to swallow and retain orally administered medication.&#xD;
&#xD;
          -  Patients must have normal organ and marrow function&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with Ewing Sarcoma. See NCT03600649, Protocol Number: SALA-002-EW16.&#xD;
&#xD;
          -  Subjects with primary central nervous system tumors&#xD;
&#xD;
          -  Patients who have not recovered to grade 1 or baseline from adverse events related to&#xD;
             prior therapy excluding lymphopenia, alopecia, peripheral neuropathy and ototoxicity,&#xD;
             which are excluded if ≥ CTCAE grade 3 (Version 5.0).&#xD;
&#xD;
          -  Patients who are receiving any other investigational agents.&#xD;
&#xD;
          -  Prior therapy with LSD1 targeted agents including monoamine oxidases for cancer&#xD;
             therapy.&#xD;
&#xD;
          -  Prior systemic anti-cancer treatment (chemotherapy, biologic therapy [ie. small&#xD;
             molecular inhibitors, monoclonal antibodies]) within 21 days prior to Cycle 1 Day 1.&#xD;
&#xD;
          -  Prior therapy with immunotherapy such as a checkpoint inhibitor, cellular therapy or&#xD;
             vaccine therapy within 28 days prior to Cycle 1 Day 1. Patients must have recovered&#xD;
             from any immune-related adverse events to grade 1 or baseline and require ≤ 10 mg of&#xD;
             prednisone equivalents daily. Patients with immune-related hypothyroidism and/or&#xD;
             hypoadrenalism may enroll while on thyroid or hydrocortisone replacement therapy,&#xD;
             respectively.&#xD;
&#xD;
          -  Prior small port palliative radiotherapy within 14 days or 42 days from definitive&#xD;
             local control radiation (any dose greater than 50Gy).&#xD;
&#xD;
          -  Anti-androgen therapies for prostate cancer, such as bicalutamide, within 4 weeks&#xD;
             prior to enrollment. Second-line hormone therapies such as enzalutamide, abiraterone,&#xD;
             or orteronel within 2 weeks prior to enrolment. Subjects with prostate cancer should&#xD;
             remain on luteinizing hormone releasing hormone (LHRH) agonists or antagonists.&#xD;
             Subjects with prostate cancer may also remain on low-dose prednisone or prednisolone&#xD;
             up to 10 mg/day&#xD;
&#xD;
          -  Prior therapy with long acting myeloid growth factor within 14 days or 7 days from a&#xD;
             short acting myeloid growth factor.&#xD;
&#xD;
          -  Participation in a prior investigational study within 30 days prior to Cycle 1 Day 1.&#xD;
&#xD;
          -  Patients with progressive or symptomatic brain metastases. Patients with brain&#xD;
             metastases may be included in this trial as long as the brain metastases have received&#xD;
             definitive treatment and are stable (i.e., no evidence of progression). The brain&#xD;
             metastases must be stable for a minimum of 6 weeks.&#xD;
&#xD;
          -  Patients must have discontinued anti-seizure medications and steroids, except for&#xD;
             physiologic steroid dosing (≤10 mg/day of prednisone equivalents).&#xD;
&#xD;
          -  Patients currently receiving any of the following substances and cannot be&#xD;
             discontinued 14 days prior to Cycle 1 Day 1: Moderate or strong inhibitors or inducers&#xD;
             of major CYP isoenzymes, including grapefruit, grapefruit hybrids, pomelos,&#xD;
             star-fruit, and Seville oranges; Moderate or strong inhibitors or inducers of major&#xD;
             drug transporters; Substrates of CYP3A4/5 with a narrow therapeutic index&#xD;
&#xD;
          -  Uncontrolled concurrent illness including, but not limited to: ongoing or active&#xD;
             infection; transfusion dependent thrombocytopenia or anemia; psychiatric&#xD;
             illness/social situations that would limit compliance with study requirements&#xD;
&#xD;
          -  Clinically significant, uncontrolled heart disease and/or cardiac repolarization&#xD;
             abnormality, including any of the following: symptomatic congestive heart failure;&#xD;
             Left Ventricular Ejection Fraction (LVEF) ≤ 50%; unstable angina pectoris or cardiac&#xD;
             arrhythmia; baseline QTcF (Fridericia) ≥ 450 milliseconds; Long QT syndrome or family&#xD;
             history of idiopathic sudden death or congenital long QT syndrome&#xD;
&#xD;
          -  Any major surgery within 21 days prior to Cycle 1 Day 1.&#xD;
&#xD;
          -  Pregnant and breastfeeding women&#xD;
&#xD;
          -  Women of child-bearing potential and men must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for&#xD;
             the duration of study participation.&#xD;
&#xD;
          -  HIV-positive patients on combination antiretroviral therapy are ineligible because of&#xD;
             the potential for pharmacokinetic interactions with SP-2577. In addition, these&#xD;
             patients are at increased risk of lethal infections when treated with&#xD;
             marrow-suppressive therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>HonorHealth</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarcoma Oncology Research Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 14, 2019</study_first_submitted>
  <study_first_submitted_qc>March 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2019</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

